

Arash Hatefi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9389254/publications.pdf>

Version: 2024-02-01

31
papers

859
citations

430874

18
h-index

477307

29
g-index

31
all docs

31
docs citations

31
times ranked

1225
citing authors

#	ARTICLE	IF	CITATIONS
1	Progress and problems with the use of suicide genes for targeted cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2016, 99, 113-128.	13.7	141
2	Enzyme/Prodrug Systems for Cancer Gene Therapy. <i>Current Pharmacology Reports</i> , 2016, 2, 299-308.	3.0	67
3	Development of recombinant cationic polymers for gene therapy research. <i>Advanced Drug Delivery Reviews</i> , 2010, 62, 1524-1529.	13.7	58
4	Genetically engineered theranostic mesenchymal stem cells for the evaluation of the anticancer efficacy of enzyme/prodrug systems. <i>Journal of Controlled Release</i> , 2015, 200, 179-187.	9.9	58
5	A designer biomimetic vector with a chimeric architecture for targeted gene transfer. <i>Journal of Controlled Release</i> , 2009, 137, 46-53.	9.9	47
6	Biosynthesis and characterization of a novel genetically engineered polymer for targeted gene transfer to cancer cells. <i>Journal of Controlled Release</i> , 2009, 138, 188-196.	9.9	44
7	A Recombinant Biopolymeric Platform for Reliable Evaluation of the Activity of pH-Responsive Amphiphile Fusogenic Peptides. <i>Biomacromolecules</i> , 2013, 14, 2033-2040.	5.4	36
8	Development of a Genetically Engineered Biomimetic Vector for Targeted Gene Transfer to Breast Cancer Cells. <i>Molecular Pharmaceutics</i> , 2009, 6, 1100-1109.	4.6	35
9	Development of targeted recombinant polymers that can deliver siRNA to the cytoplasm and plasmid DNA to the cell nucleus. <i>Journal of Controlled Release</i> , 2011, 151, 95-101.	9.9	32
10	Evaluation of the effect of vector architecture on DNA condensation and gene transfer efficiency. <i>Journal of Controlled Release</i> , 2008, 129, 117-123.	9.9	31
11	HSV-TK/GCV cancer suicide gene therapy by a designed recombinant multifunctional vector. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2011, 7, 193-200.	3.3	31
12	Incorporation of histone derived recombinant protein for enhanced disassembly of core-membrane structured liposomal nanoparticles for efficient siRNA delivery. <i>Journal of Controlled Release</i> , 2013, 172, 179-189.	9.9	28
13	Advances with the use of bio-inspired vectors towards creation of artificial viruses. <i>Expert Opinion on Drug Delivery</i> , 2010, 7, 497-512.	5.0	27
14	Development of a novel histone H1-based recombinant fusion peptide for targeted non-viral gene delivery. <i>International Journal of Pharmaceutics</i> , 2013, 441, 307-315.	5.2	25
15	Bispecific antibody complex pre-targeting and targeted delivery of polymer drug conjugates for imaging and therapy in dual human mammary cancer xenografts. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1603-1616.	6.4	24
16	Systematic Engineering of Uniform, Highly Efficient, Targeted and Shielded Viral Mimetic Nanoparticles. <i>Small</i> , 2013, 9, 2774-2783.	10.0	23
17	Reducing the Visibility of the Vector/DNA Nanocomplexes to the Immune System by Elastin-Like Peptides. <i>Pharmaceutical Research</i> , 2015, 32, 3018-3028.	3.5	22
18	Perspectives in vector development for systemic cancer gene therapy. <i>Gene Therapy and Molecular Biology</i> , 2009, 13, 15-19.	1.3	20

#	ARTICLE	IF	CITATIONS
19	Bioengineered adipose-derived stem cells for targeted enzyme-prodrug therapy of ovarian cancer intraperitoneal metastasis. <i>Journal of Controlled Release</i> , 2019, 311-312, 273-287.	9.9	17
20	Bioengineering a non-genotoxic vector for genetic modification of mesenchymal stem cells. <i>Biomaterials</i> , 2018, 152, 1-14.	11.4	14
21	Advances in recombinant polymers for delivery of bioactive agents. <i>Advanced Drug Delivery Reviews</i> , 2010, 62, 1403.	13.7	13
22	Bispecific antibody complex pre-targeted delivery of polymer-drug conjugates for cancer therapy. <i>Drug Delivery and Translational Research</i> , 2012, 2, 65-76.	5.8	13
23	Practical Issues with the Use of Stem Cells for Cancer Gene Therapy. <i>Stem Cell Reviews and Reports</i> , 2015, 11, 688-698.	5.6	9
24	A novel chemotherapeutic protocol for peritoneal metastasis and inhibition of relapse in drug resistant ovarian cancer. <i>Cancer Medicine</i> , 2018, 7, 3630-3641.	2.8	9
25	Production of low-expressing recombinant cationic biopolymers with high purity. <i>Protein Expression and Purification</i> , 2017, 134, 11-17.	1.3	7
26	Development of a Recombinant Multifunctional Biomacromolecule for Targeted Gene Transfer to Prostate Cancer Cells. <i>Biomacromolecules</i> , 2017, 18, 2799-2807.	5.4	7
27	Gadolinium-labeled affibody-XTEN recombinant vector for detection of HER2+ lesions of ovarian cancer lung metastasis using quantitative MRI. <i>Journal of Controlled Release</i> , 2021, 337, 132-143.	9.9	6
28	Advances in image-guided drug delivery. <i>Drug Delivery and Translational Research</i> , 2012, 2, 1-2.	5.8	5
29	Evaluation of genotoxicity and mutagenic effects of vector/DNA nanocomplexes in transfected mesenchymal stem cells by flow cytometry. <i>Acta Biomaterialia</i> , 2018, 74, 236-246.	8.3	5
30	An <i>in vitro</i> demonstration of overcoming drug resistance in SKOV3 TR and MCF7 ADR with targeted delivery of polymer pro-drug conjugates. <i>Journal of Drug Targeting</i> , 2017, 25, 436-450.	4.4	3
31	Gene-Directed Enzyme Prodrug Cancer Therapy. , 2014, , 77-91.		2